Selected phlebological abstracts.

The article focuses on investigating the pharmacokinetic and pharmacodynamic profiles of direct-acting oral anticoagulants (DOACs) in treating patients at extremes of body weight, highlighting the efficacy and safety of apixaban and rivaroxaban in obese patients and the reduced dosage of edoxaban in low-weight patients. Topics include the comparative effectiveness of DOACs in venous thromboembolism (VTE) treatment and prevention of cardioembolic stroke in nonvalvular atrial fibrillation (NVAF).